Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company Jul 22, 2021 09:15AM
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement Jun 10, 2021 05:12PM
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger May 6, 2021 05:31PM
CM Life Sciences, Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about October 26, 2020 Oct 23, 2020 06:01PM
CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $442.75 Million Initial Public Offering Sep 4, 2020 12:22PM